Nu Skin Enterprises (NUS) reported $1.5B in revenue for fiscal 2025, −14.3% year on year. That ranks #1517 by revenue among 2853 SEC filers and #135 in Healthcare. Net income was $160M, a net margin of 10.8%. Revenue has declined 1.0% a year on average since 2011 ($1.7B then). The fiscal 2025 balance sheet shows $1.4B in total assets, $239M in cash and $204M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.5B | −14.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $1.0B | −12.7% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $65.8M | +$217M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $160M | +$307M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $80.3M | −28.2% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $34.3M | −17.6% | FY20252025-12-31 |
| Total assetsAssets | $1.4B | −4.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $805M | +23.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $239M | +27.7% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $204M | −43.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $321M | $1.8M | Open → |
| Q2 20262026-06-30 | $320M | −$250M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 52 of 161 companies compared | 10.8% | |
| Operating marginRank 109 of 160 companies compared | 4.4% | |
| R&D as share of revenueRank 96 of 102 companies compared | 0.7% | |
| Cash as share of revenueRank 64 of 160 companies compared | 16.1% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Nu Skin Enterprises, Inc.
- Ticker
- NUS
- Exchange
- NYSE
- SIC classification
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- Fiscal year end
- 12-31
- CIK
- 0001021561
Filings
- 10-QAug 10, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 13, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Lantheus HoldingsLNTH | $1.5B | $234M |
| National HealthcareNHC | $1.5B | $120M |
| Merit Medical SystemsMMSI | $1.5B | $128M |
| Nu Skin EnterprisesNUS | $1.5B | $160M |
| AlkermesALKS | $1.5B | $242M |
| P3 Health PartnersPIII | $1.5B | −$148M |
| Guardian Pharmacy ServicesGRDN | $1.4B | $49.2M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Nu Skin Enterprises — Key figures |url=https://companiesranked.com/en/company/nu-skin-enterprises |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Nu Skin Enterprises — Key figures. CompaniesRanked. https://companiesranked.com/en/company/nu-skin-enterprisesBibTeX
@misc{companiesranked-en-company-nu-skin-enterprises-2026,
author = {{CompaniesRanked}},
title = {{Nu Skin Enterprises — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/nu-skin-enterprises}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001140361-26-005130 · February 13, 2026
{{cite web |title=Nu Skin Enterprises — Key figures — 10-K (0001140361-26-005130) |url=https://www.sec.gov/Archives/edgar/data/1021561/000114036126005130/ef20060638_10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-13}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.